• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Orchestra BioMed Holdings Inc.

    2/6/26 4:15:42 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $OBIO alert in real time by email
    S-8 1 tm265026d2_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 6, 2026

    Registration No. 333-              

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ORCHESTRA BIOMED HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   92-2038755

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    150 Union Square Drive

    New Hope, Pennsylvania 18928

    (Address of Principal Executive Offices) (Zip Code)

     

    Orchestra BioMed Holdings, Inc. 2025 New Hire Inducement Plan

    (Full titles of the plans)

     

    David P. Hochman

    Chief Executive Officer

    150 Union Square Drive

    New Hope, PA 18928

    (215) 862-5797

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Yariv Katz, Esq.

    Keith Pisani, Esq.

    Paul Hastings LLP

    200 Park Avenue

    New York, NY 10016

    (212) 318-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

                 
    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   x   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    EXPLANATORY NOTE; INCORPORATION BY REFERENCE OF CONTENTS OF
    REGISTRATION STATEMENTS ON FORM S-8

     

    Orchestra BioMed Holdings, Inc. (the “Registrant” or the “Company”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register 950,000 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Registrant reserved for issuance under the Orchestra BioMed Holdings, Inc. 2025 New Hire Inducement Plan (the “Inducement Plan”).

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The document(s) containing the information specified in Part I will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

     

    The following documents filed by the Registrant with the SEC are hereby incorporated by reference into this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025;

     

    (b) The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025, for the quarter ended June 30, 2025, filed with the SEC on August 12, 2025, and for the quarter ended September 30, 2025, filed with the SEC on November 10, 2025;

     

    (c) The Registrant’s Current Reports on Form 8-K, filed with SEC on February 5, 2025 (excluding the information furnished under Item 7.01), February 25, 2025, April 29, 2025 (excluding the information furnished under Item 7.01), June 24, 2025, July 31, 2025 (excluding the information furnished under Item 7.01), August 4, 2025 (excluding the information furnished under Item 7.01), October 28, 2025 (excluding the information furnished under Item 7.01) and January 12, 2026; and

     

    (d) The description of the Registrant’s Common Stock contained in Exhibit 4.18 to the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025, including any amendment or reports filed for the purpose of updating such description.

     

    All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.

     

    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    2 

     

     

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

     

    You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:

     

    Orchestra BioMed Holdings, Inc.

    150 Union Square Drive

    New Hope, PA 18938

    Attn: Chief Executive Officer

     

    ITEM 4. DESCRIPTION OF SECURITIES.

     

    Not applicable.

     

    ITEM 5. INTEREST OF NAMED EXPERTS AND COUNSEL.

     

    Not applicable.

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

     

    Section 102 of the General Corporation Law of the State of Delaware (“DGCL”) permits a corporation to eliminate or limit the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or derived an improper personal benefit, or, with respect to any officer, any action by or in the right of the corporation. The Registrant’s certificate of incorporation (the “Certificate of Incorporation”) contains provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the DGCL. Consequently, the Registrant’s directors and officers will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, except liability for the following:

     

    ·any breach of their duty of loyalty to the Registrant or its stockholders;

     

    ·acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

     

    ·with respect to any director, unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL;

     

    ·any transaction from which the director derived an improper personal benefit; or

     

    ·with respect to any officer, any action by or in the right of the corporation.

     

    The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of the Registrant’s directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

     

    3 

     

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with such action, suit or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The Certificate of Incorporation permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant’s bylaws (the “Bylaws”) provide that the Registrant will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law.

     

    The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors’ and officers’ liability insurance.

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

     

    Not applicable.

     

    4 

     

     

    ITEM 8. EXHIBITS.

     

    Exhibit
    Number
      Description
    4.1   Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on January 31, 2023).
       
    4.2   Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by the Registrant on November 10, 2025)
       
    4.3   Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by the Registrant on August 12, 2024).
       
    5.1*   Opinion of Paul Hastings LLP.
       
    23.1*   Consent of Ernst & Young LLP, independent registered public accounting firm of the Registrant.
       
    23.2*   Consent of Paul Hastings LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney is contained on the signature page.
       
    99.1#   Orchestra BioMed Holdings, Inc. 2025 New Hire Inducement Plan (incorporated by reference to Exhibit 10.13 to the Quarterly Report on Form 10-Q filed by the Registrant on November 10, 2025).
       
    99.2#   Form of Stock Option Grant Notice and Stock Option Agreement for the Orchestra BioMed Holdings, Inc. 2025 New Hire Inducement Plan (incorporated by reference to Exhibit 10.14 to the Quarterly Report on Form 10-Q filed by the Registrant on November 10, 2025).
       
    99.3#   Form of Restricted Stock Unit Grant Notice and Award Agreement for the Orchestra BioMed Holdings, Inc. 2025 New Hire Inducement Plan (incorporated by reference to Exhibit 10.15 to the Quarterly Report on Form 10-Q filed by the Registrant on November 10, 2025).
         
    107*   Filing Fee Table

     

    * Filed herewith.
    #  Indicates a management contract or compensatory plan.

     

    5 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in city of New York, State of New York, on February 6, 2026.

     

      ORCHESTRA BIOMED HOLDINGS, INC.
         
      By: /s/ David P. Hochman
      Name: David P. Hochman
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David P. Hochman and Andrew L. Taylor, and each or any one of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE   TITLE   DATE
           

    /s/ David P. Hochman

    David P. Hochman

     

    Chief Executive Officer, Chairperson and Director

    (Principal Executive Officer)

      February 6, 2026
         

    /s/ Andrew L. Taylor

    Andrew L. Taylor

     

    Chief Financial Officer

    (Principal Financial Officer)

      February 6, 2026
         

    /s/ Joshua Aiello

    Joshua Aiello

     

    Corporate Controller

    (Principal Accounting Officer)

      February 6, 2026
           

    /s/ Jason Aryeh

    Jason Aryeh

     

      Director   February 6, 2026

    /s/ Chris Cleary

    Chris Cleary

     

      Director   February 6, 2026

    /s/ Pamela A. Connealy

    Pamela A. Connealy

      Director   February 6, 2026
         

    /s/ Eric S. Fain, M.D.

    Eric S. Fain, M.D.

      Director   February 6, 2026
         

    /s/ David Pacitti

      Director   February 6, 2026

    David Pacitti

     

       

    /s/ John Mack

    John Mack

     

      Director   February 6, 2026

    /s/ Darren R. Sherman

    Darren R. Sherman

      Chief Operating Officer and Director   February 6, 2026

     

    6 

     

    Get the next $OBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OBIO

    DatePrice TargetRatingAnalyst
    12/10/2025$15.00Buy
    TD Cowen
    8/20/2025Buy → Neutral
    BTIG Research
    3/20/2025$12.00Buy
    BTIG Research
    1/2/2025$16.00Overweight
    Barclays
    8/22/2024$14.00Buy
    H.C. Wainwright
    7/25/2024$15.00Buy
    B. Riley Securities
    1/19/2024$14.00Buy
    Jefferies
    2/24/2023$15.00Overweight
    Piper Sandler
    More analyst ratings

    $OBIO
    SEC Filings

    View All

    SEC Form S-8 filed by Orchestra BioMed Holdings Inc.

    S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    2/6/26 4:15:42 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Orchestra BioMed Holdings Inc.

    S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    2/6/26 4:15:29 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    1/12/26 9:12:25 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

    $11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnoutsVivasure Medical Limited ("Vivasure") has been a strategic holding of Orchestra BioMed since the Company's formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it expects to receive up to $21 million in cash proceeds in connection with the acquisition of Vivasure, an Ireland-based company pioneering next-generation techn

    1/12/26 9:00:00 AM ET
    $HAE
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    Vivasure Medical Announces Acquisition by Haemonetics Corporation

    Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE:HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones. Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology, and vascular surgery. In 2022, Vivasure Medical received a strategic investment from Haemonetics, which included an option to acquire Vivasure Medical. Earlier this year, Vivasure Medical announced the sub

    1/9/26 8:00:00 AM ET
    $HAE
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

    Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker NEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced three presentations at the 2025 Innovation in Cardiology Intervention ("ICI") meeting in Tel Aviv, Israel, including two presentations focused on Atrioventricular Interval Modulatio

    12/8/25 7:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $OBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orchestra BioMed with a new price target

    TD Cowen initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

    12/10/25 8:29:27 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed downgraded by BTIG Research

    BTIG Research downgraded Orchestra BioMed from Buy to Neutral

    8/20/25 8:28:57 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    BTIG Research initiated coverage on Orchestra BioMed with a new price target

    BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

    3/20/25 8:00:48 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hochman David P bought $20,350 worth of shares (5,000 units at $4.07), increasing direct ownership by 0.82% to 612,822 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    11/17/25 5:00:21 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Aryeh Jason bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 0.93% to 108,482 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 6:57:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fain Eric S bought $15,034 worth of shares (5,760 units at $2.61) (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    8/25/25 7:04:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cleary Chris covered exercise/tax liability with 676 shares, decreasing direct ownership by 2% to 36,901 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/6/26 4:16:33 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Officer Sherman Darren

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/6/26 4:15:16 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,452 shares, decreasing direct ownership by 0.76% to 451,493 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    1/2/26 6:55:28 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

    The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

    2/18/25 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

    Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

    2/5/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $OBIO
    Financials

    Live finance-specific insights

    View All

    Orchestra BioMed to Host Business Update Call on November 12, 2025

    NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing developments, including the Company's additional strategic investment from and collaboration expansion with Medtronic, its new strategic capital relationship with Ligand, its new right of first refusal agr

    11/3/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

    Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc

    9/19/23 7:30:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $OBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

    SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    8/7/24 5:19:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

    SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    8/7/24 5:16:55 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

    SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    7/17/24 4:32:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care